Featured Research

from universities, journals, and other organizations

Patients At Increased Risk Of Heart Attack Within 3 Months After Stopping Clopidogrel Therapy, Study Shows

Date:
February 11, 2008
Source:
JAMA and Archives Journals
Summary:
Patients who receive the anti-platelet medication clopidogrel following an acute coronary syndrome (such as heart attack) appear to be at greater risk of a heart attack or death in the first 90 days after stopping clopidogrel treatment, according to a new study.

Patients who receive the anti-platelet medication clopidogrel following an acute coronary syndrome (such as heart attack) appear to be at greater risk of a heart attack or death in the first 90 days after stopping clopidogrel treatment, according to a new study.

Randomized trials have established the effectiveness of clopidogrel therapy following hospitalization for acute coronary syndrome (ACS) for patients treated either medically or with percutaneous coronary intervention (PCI - procedures such as balloon angioplasty or stent placement used to open narrowed coronary arteries). Current cardiology guidelines recommend clopidogrel therapy for ideally up to 1 year for patients treated medically or with a bare metal stent, according to background information in the article. It is unknown whether there may be a "rebound effect" or concentration of thrombotic events shortly after stopping treatment with clopidogrel, as has been found for patients after long-term aspirin therapy.

P. Michael Ho, M.D., Ph.D., of the Denver VA Medical Center, Denver, and colleagues assessed the incidence and timing of death or acute myocardial infarction (AMI; heart attack) after stopping treatment with clopidogrel in a group of 3,137 patients with ACS discharged from 127 Veterans Affairs hospitals. Average follow-up after stopping treatment with clopidogrel was 196 days for medically treated patients with ACS without stents (n = 1,568) and 203 days for patients with ACS treated with PCI (n = 1,569).

Among the medically-treated patients, the average duration of clopidogrel treatment was 302 days. The researchers found that all-cause death (n = 155) or AMI (n = 113) occurred in 17.1 percent (n = 268) of patients, with 60.8 percent (n = 163) of events occurring during 0 to 90 days, 21.3 percent (n = 57) occurring during 91 to 180 days, and 9.7 percent (n = 26) occurring during 181 to 270 days after stopping treatment with clopidogrel. Further analysis indicated that the interval of 0 to 90 days was associated with nearly twice the risk of adverse events after stopping treatment with clopidogrel compared with the interval of 91 to 180 days.

Among the PCI-treated patients, average duration of clopidogrel treatment was 278 days. All-cause death (n = 68) or AMI (n = 56) occurred in 7.9 percent (n = 124) of the patients, with 58.9 percent (n = 73) of the events occurring during 0 to 90 days, 23.4 percent (n = 29) occurring during 91 to 180 days, and 6.5 percent (n = 8) occurring during 181 to 270 days after stopping treatment with clopidogrel. After adjustment for total duration of clopidogrel treatment following hospital discharge, the interval of 0 to 90 days after stopping treatment with clopidogrel was associated with an 82 percent increased risk of adverse events compared with the interval of 91 to 180 days.

The authors write that there is in vitro and physiological evidence to support a short-term increase in platelet activation and associated thrombotic risk immediately after stopping antiplatelet therapy.

"There are several potential implications of this study. Even though the absolute event rates were low, the relative increase in adverse events in the early period after stopping treatment with clopidogrel was nearly 2-fold higher than later periods. In addition, the absolute number of adverse events attributable to this event clustering is significant when extrapolated to a population level, considering the number of patients admitted with ACS and discharged with posthospital treatment with clopidogrel therapy both in the United States and worldwide."

"These findings, however, do not necessarily offset the benefits of clopidogrel therapy. Rather, additional studies are needed to confirm the presence of the event clustering after cessation of clopidogrel and to better understand the pathophysiology of this phenomenon. If these findings are subsequently confirmed, guideline recommendations may need to be reconsidered in terms of duration of clopidogrel therapy and perhaps the means of drug cessation," the researchers conclude.

Journal reference: JAMA. 2008;299[5]:532-539.


Story Source:

The above story is based on materials provided by JAMA and Archives Journals. Note: Materials may be edited for content and length.


Cite This Page:

JAMA and Archives Journals. "Patients At Increased Risk Of Heart Attack Within 3 Months After Stopping Clopidogrel Therapy, Study Shows." ScienceDaily. ScienceDaily, 11 February 2008. <www.sciencedaily.com/releases/2008/02/080205161253.htm>.
JAMA and Archives Journals. (2008, February 11). Patients At Increased Risk Of Heart Attack Within 3 Months After Stopping Clopidogrel Therapy, Study Shows. ScienceDaily. Retrieved April 19, 2014 from www.sciencedaily.com/releases/2008/02/080205161253.htm
JAMA and Archives Journals. "Patients At Increased Risk Of Heart Attack Within 3 Months After Stopping Clopidogrel Therapy, Study Shows." ScienceDaily. www.sciencedaily.com/releases/2008/02/080205161253.htm (accessed April 19, 2014).

Share This



More Health & Medicine News

Saturday, April 19, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

'Holy Grail' Of Weight Loss? New Find Could Be It

'Holy Grail' Of Weight Loss? New Find Could Be It

Newsy (Apr. 18, 2014) In a potential breakthrough for future obesity treatments, scientists have used MRI scans to pinpoint brown fat in a living adult for the first time. Video provided by Newsy
Powered by NewsLook.com
Little Progress Made In Fighting Food Poisoning, CDC Says

Little Progress Made In Fighting Food Poisoning, CDC Says

Newsy (Apr. 18, 2014) A new report shows rates of two foodborne infections increased in the U.S. in recent years, while salmonella actually dropped 9 percent. Video provided by Newsy
Powered by NewsLook.com
Scientists Create Stem Cells From Adult Skin Cells

Scientists Create Stem Cells From Adult Skin Cells

Newsy (Apr. 17, 2014) The breakthrough could mean a cure for some serious diseases and even the possibility of human cloning, but it's all still a way off. Video provided by Newsy
Powered by NewsLook.com
Obama: 8 Million Healthcare Signups

Obama: 8 Million Healthcare Signups

AP (Apr. 17, 2014) President Barack Obama gave a briefing Thursday announcing 8 million people have signed up under the Affordable Care Act. He blasted continued Republican efforts to repeal the law. (April 17) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins